Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective ...

As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...

The FDA reportedly told drugmakers that approved monoclonal antibodies to protect infants against respiratory syncytial virus ...

In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...

FDA officials are newly scrutinizing several approved therapies to treat RSV in babies despite the fact that these shots were shown to be safe in clinical trials ...

Among adults older adults, a respiratory syncytial virus (RSV) infection increases the risk of cardiovascular events over the ...

Respiratory syncytial virus, commonly known as RSV, is often associated with cold-like symptoms in young children.

Early-life viral infection programs immune cells to hijack allergy-associated maternal antibodies, driving allergy risk later ...

Recovering from respiratory syncytial virus often doesn't end when it's time to leave the hospital, even for younger adults.